Clinical Efficacy And Safety Observation Of Calcium Sensitizer In The Treatment Of Decompensated Patients With Chronic Heart Failure

Objective: To discuss the efficacy and safety of calcium sensitizer(levosimendan)in treatment of chronic decompensated congestive heart failure.Methods: Totally 97 patients(NYHA heart function classification level III to IV)with chronic decompensated congestive heart failure were chosen from our Hospital from October 2016 to October 2017.They were randomly divided into two groups.45 cases in the conventional treatment group and 52 cases in the levosimendan group.the two groups were applied administration of conventional standardized treatment for heart failure(includes diuretics,aldosterone receptor antagonists,digitalis,ACEI/ARB,beta blockers,etc.),otherwise,the levosimendan group was treated with intravenous levosimendan in addition to conventional treatment.The left ventricular ejection fraction(LVEF)was measured in the first 24 hour of admission and on the 7th day of treatment,Plasma NT-pro BNP,biochemical indicators(creatinine,ALT,AST)were collected in the early morning and the estimated glomerular filtration rate(e GFR)was calculated.To evaluate NYHA heart functional class before and after treatment in both groups.Results: On the 7th day of treatment,the LVEF,NT-pro BNP,urine volume,and NYHA heart functional class were improved in both the conventional treatment group and the levosimendan group,the difference was statistically significant(P <0.05).However,the levosimendan group had higher LVEF,lower NT-pro BNP,and higher urine volume than the conventional treatment group,the cardiac function classification of New York improved more significantly(P<0.05).Before and after treatment,Two groups of patients liver function and renal function,e GFR there was no significant difference(P > 0.05).Conclusion: Early application of levosimendan in the treatment of chronic heart failure decompensated patients can significantly improve heart failure index,such as LVEF,NT-pro BNP,urine output,NYHA heart function classification.It dose not damage liver and kidney function,and have good clinical effect.